Lonnie Moulder

Lonnie Moulder has been a director since 2019.

Mr. Moulder is the Founding General Partner of Tellus Bio Ventures, LLC, an early-stage life sciences investment fund. He most recently served as CEO and Director of TESARO, Inc. since cofounding the company in 2010. Acquired by GlaxoSmithKline (GSK) in January 2019, TESARO was a fully-integrated Boston based oncology-focused biopharmaceutical company with operations in North America and Europe.

He previously served as President and CEO of Abraxis BioScience, Inc., prior to the company’s eventual acquisition by Celgene Corporation in 2010. In 2008 Lonnie served as Vice Chairman of Eisai Corporation of North America following Eisai’s acquisition of MGI PHARMA, where he served as President and CEO beginning in 2003 and previously Executive Vice President since 1999. This followed him serving as a member of the founding management team of a venture-stage biotech company in 1997.

Mr. Moulder began his career as a clinical pharmacist followed by a seventeen year career at predecessor companies of Sanofi, beginning with Marion Laboratories in 1981.

Mr. Moulder is a Temple University Trustee, Chair of the Trustee Committee for Research and Chair of the Temple University Japan (TESS) Board. He is a Council Member for both the University of Chicago Booth School of Business and the Polsky Center for Entrepreneurship and Innovation. Mr. Moulder is Chair of the Board of Directors of Trevena, Inc. and previously served on the Boards of Cubist Pharmaceuticals and the Biotechnology Innovation Organization (BIO). Mr. Moulder received a Pharmacy degree from Temple University in 1980 and an MBA from The University of Chicago Booth School of Business in 1997.